Novo Nordisk A/S is undercutting arch-rival Eli Lilly & Co. on obesity drugs for cash-pay patients, showing its willingness to compete on price as it tries to claw back a larger share of the US market.
www.bloomberg.com
#Novo #Undercuts #Lillys #Obesity #Drug #Price #CashPay #Patients
Former Indian Ambassador to Iran & the United Arab Emirates Krishan Chander Singh breaks down India’s challenging strategic position in…
Firms enabling payments are seen as staid and less safe than once believed, ousting them from index benchmarks. www.bloomberg.com #French #Payments #Werent…
Crude shipments registered their biggest week-on-week drop since the invasion of Ukraine www.bloomberg.com #Russias #War #Chest #Hammered #Oil #Flows #Prices #Plunge Related reading:Iran…
